Completing data — refresh the page later to see the latest
300-39-0N[C@@H](Cc1cc(I)c(O)c(I)c1)C(=O)ONYPYHUZRZVSYKL-ZETCQYMHSA-N300-39-0DTXSID0048680CHEMBL1236469CHEBI:157680.617 mg/mL at 25 °C
>64.9 [ug/mL] (The mean of the results at pH 7.4)
159.3 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)];165.2 Ų [M+Na]+ [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)];171.1 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
This chemical does not meet GHS hazard criteria for 14.3% (2 of 14) of reports.
Warning
H315 (85.7%): Causes skin irritation [Warning Skin corrosion/irritation];H319 (85.7%): Causes serious eye irritation [Warning Serious eye damage/eye irritation];H335 (85.7%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 14 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.;Reported as not meeting GHS hazard criteria per 2 of 14 reports by companies.;There are 3 notifications provided by 12 of 14 reports by companies with hazard statement code(s).;Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
H - Systemic hormonal preparations, excl. sex hormones and insulins;H03 - Thyroid therapy;H03B - Antithyroid preparations;H03BX - Other antithyroid preparations;H03BX01 - Diiodotyrosine
QH - Systemic hormonal preparations, excl. sex hormones and insulin;QH03 - Thyroid therapy;QH03B - Antithyroid preparations;QH03BX - Other antithyroid preparations;QH03BX01 - Diiodotyrosine
DescriptionDiiodotyrosine does not possess pronounced hormonal activity. However, it stops production of thyrotropic hormone by the anterior lobe of the hypophysis, which activates thyroid gland activity.
UsesIt is used for hyperthyroid forms of endemic and sporadic goiters, diffuse, toxic goiters, and other illnesses accompanied by thyrotoxicity.
Uses3,5-Diiodo-L-tyrosine is a reactant used in the synthesis of fluorescent unnatural amino acids bearing stilbene or vinylene backbones. Also used in the discovery of potent heterodimeric antagonists of inhibitor of Apoptosis proteins with prolonged anti-tumor activity.
Uses3,5-Diiodo-L-tyrosine Dihydrate is a thyroid hormone receptor agonist.
Loading…
Loading…
Loading…
DefinitionChEBI: A diiodotyrosine that is L-tyrosine carrying iodo-substituents at positions C-3 and C-5 of the benzyl group. It is an intermediate in the thyroid hormone synthesis.